Management of perihilar cholangiocarcinoma in the era of multimodal therapy

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 4, 2012, Pages 481-495

  Valero, Vicente ^a   Cosgrove, David ^b   Herman, Joseph M ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cholangiocarcinoma; hilar; multimodality; outcome; perihilar

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; PHOTOSENSITIZING AGENT; SORAFENIB;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BILIARY TRACT ENDOSCOPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEPATIC DUCT; HUMAN; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PHOTODYNAMIC THERAPY; PORTAL VEIN; PORTAL VEIN EMBOLIZATION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIMARY SCLEROSING CHOLANGITIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; COMBINED MODALITY THERAPY; ENDOSCOPY, DIGESTIVE SYSTEM; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 84865797871     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.20     Document Type: Review

References (135)

1. Altemeier WA, Gall EA, Zinninger MM, Hoxworth PI. Sclerosing carcinoma of the major intrahepatic bile ducts. AMA. Arch. Surg.75(3), 450-60; discussion 460 (1957).
2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. an unusual tumor with distinctive clinical and pathological features. Am. J. Med. 38, 241-256 (1965).
3. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann. Surg. 250(2), 210-218 (2009).
4. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann. Surg. 228(3), 385-394 (1998). (Pubitemid 30191701)
5. DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245(5), 755-762 (2007). (Pubitemid 46684105)
6. Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224(4), 463-473; discussion 473 (1996).
7. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J. Hepatol. 40(3), 472-477 (2004). (Pubitemid 38230849)
8. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev. 15(6), 1198-1203 (2006).
9. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R; AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig. Liver Dis. 42(7), 490-495 (2010).
10. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 24(2), 115-125 (2004). (Pubitemid 38738341)
11. Khan SA, Emadossadaty S, Ladep NG et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J. Hepatol. 56(4), 848-854 (2011).
12. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J. Natl Cancer Inst. 98(12), 873-875 (2006). (Pubitemid 43923444)
13. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002).
14. Welzel TM, Graubard BI, El-Serag HB et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case- control study. Clin. Gastroenterol. Hepatol. 5(10), 1221-1228 (2007). (Pubitemid 47496233)
15. Choi D, Lim JH, Lee KT et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. J. Hepatol. 44(6), 1066-1073 (2006).
16. Parkin DM, Srivatanakul P, Khlat M et al. Liver cancer in Thailand. I. A case- control study of cholangiocarcinoma. Int. J. Cancer 48(3), 323-328 (1991).
17. Chalasani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31(1), 7-11 (2000). (Pubitemid 30033681)
18. Bergquist A, Glaumann H, Persson B, Broomé U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27(2), 311-316 (1998). (Pubitemid 28081041)
19. Broomé U, Olsson R, Lööf L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38(4), 610-615 (1996). (Pubitemid 26111384)
20. Aadland E, Schrumpf E, Fausa O et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22(6), 655-664 (1987). (Pubitemid 17134654)
21. Nordenstedt H, Mattsson F, El-Serag H, Lagergren J. Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. Br. J. Cancer 106(5), 1011-1015 (2012).
22. Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann. Surg. 220(5), 644-652 (1994). (Pubitemid 24355776)
23. Chijiiwa K, Koga A. Surgical management and long-term follow-up of patients with choledochal cysts. Am. J. Surg. 165(2), 238-242 (1993). (Pubitemid 23281374)
24. Choi BI, Han JK, Hong ST, Lee KH. Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. Clin. Microbiol. Rev. 17(3), 540-552 (2004). (Pubitemid 38970681)
25. Hong ST, Kho WG, Kim WH, Chai JY, Lee SH. Turnover of biliary epithelial cells in Clonorchis sinensis infected rats. Korean J. Parasitol. 31(2), 83-89 (1993).
26. Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br. J. Surg. 83(8), 1062-1064 (1996). (Pubitemid 26291207)
27. Wetter LA, Ring EJ, Pellegrini CA, Way LW. Differential diagnosis of sclerosing cholangiocarcinomas of the common hepatic duct (Klatskin tumors). Am. J. Surg. 161(1), 57-62; discussion 62 (1991).
28. Verbeek PC, van Leeuwen DJ, de Wit LT et al. Benign fibrosing disease at the hepatic confluence mimicking Klatskin tumors. Surgery 112(5), 866-871 (1992).
29. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95(1), 204-207 (2000). (Pubitemid 30041560)
30. Juntermanns B, Radunz S, Heuer M et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur. J. Med. Res. 15(8), 357-361 (2010).
31. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin. Gastroenterol. Hepatol. 9(5), 434-439.e1 (2011).
32. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108(3), 865-869 (1995).
33. Gakhal MS, Gheyi VK, Brock RE, Andrews GS. Multimodality imaging of biliary malignancies. Surg. Oncol. Clin. N. Am. 18(2), 225-239, vii (2009).
34. Unno M, Okumoto T, Katayose Y et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J. Hepatobiliary. Pancreat. Surg. 14(5), 434-440 (2007). (Pubitemid 47517210)
35. Chen HW, Lai EC, Pan AZ, Chen T, Liao S, Lau WY. Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. Hepatogastroenterology 56(91-92), 578-583 (2009).
36. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J. Hepatol. 45(6), 856-867 (2006). (Pubitemid 44646688)
37. Rösch T, Meining A, Frühmorgen S et al. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest. Endosc. 55(7), 870-876 (2002). (Pubitemid 41127905)
38. Reinhold C, Bret PM. Current status of MR cholangiopancreatography. AJR. Am. J. Roentgenol. 166(6), 1285-1295 (1996). (Pubitemid 26160577)
39. Zidi SH, Prat F, Le Guen O, Rondeau Y, Pelletier G. Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut 46(1), 103-106 (2000). (Pubitemid 30307686)
40. Sai JK, Suyama M, Kubokawa Y, Watanabe S, Maehara T. Early detection of extrahepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest. Endosc. 70(1), 29-36 (2009).
41. Cho ES, Park MS, Yu JS, Kim MJ, Kim KW. Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J. Comput. Assist. Tomogr. 31(1), 72-78 (2007). (Pubitemid 46183344)
42. Cui XY, Chen HW. Role of diffusionweighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma. World J. Gastroenterol. 16(25), 3196-3201 (2010).
43. Keiding S, Hansen SB, Rasmussen HH et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 28(3), 700-706 (1998). (Pubitemid 28405419)
44. Prytz H, Keiding S, Björnsson E et al.; Swedish Internal Medicine Liver Club. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44(6), 1572-1580 (2006). (Pubitemid 44953662)
45. Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J. Hepatol. 45(1), 43-50 (2006). (Pubitemid 43850623)
46. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg. 8(1), 90-97 (2004). (Pubitemid 38117282)
47. Park MS, Kim TK, Kim KW et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 233(1), 234-240 (2004). (Pubitemid 39280979)
48. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur. J. Surg. Oncol. 31(5), 533-539 (2005). (Pubitemid 40724095)
49. Ponchon T, Gagnon P, Berger F et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest. Endosc. 42(6), 565-572 (1995).
50. Sugiyama M, Atomi Y, Wada N, Kuroda A, Muto T. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am. J. Gastroenterol. 91(3), 465-467 (1996). (Pubitemid 26083547)
51. Kubota Y, Takaoka M, Tani K et al. Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal strictures. Am. J. Gastroenterol. 88(10), 1700-1704 (1993). (Pubitemid 23298117)
52. Tamada K, Tomiyama T, Wada S et al. Endoscopic transpapillary bile duct biopsy with the combination of intraductal ultrasonography in the diagnosis of biliary strictures. Gut 50(3), 326-331 (2002). (Pubitemid 34161046)
53. Tamada K, Satoh Y, Tomiyama T et al. Multiple bile duct biopsies using a sheath with a side port: usefulness of intraductal sonography. AJR. Am. J. Roentgenol. 176(3), 797-802 (2001). (Pubitemid 32181990)
54. Ferrero A, Lo Tesoriere R, Viganò L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J. Surg. 33(2), 318-325 (2009).
55. Chen YK, Pleskow DK. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest. Endosc. 65(6), 832-841 (2007). (Pubitemid 46629073)
56. Fukuda Y, Tsuyuguchi T, Sakai Y, Tsuchiya S, Saisyo H. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest. Endosc. 62(3), 374-382 (2005). (Pubitemid 41187939)
57. Fishman DS, Tarnasky PR, Patel SN, Raijman I. Management of pancreaticobiliary disease using a new intra-ductal endoscope: the Texas experience. World J. Gastroenterol. 15(11), 1353-1358 (2009).
58. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet. 140(2), 170-178 (1975).
59. Jarnagin WR, Fong Y, DeMatteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 234(4), 507-17; discussion 517 (2001).
60. Chen RF, Li ZH, Zhou JJ et al. Preoperative evaluation with T-staging system for hilar cholangiocarcinoma. World J. Gastroenterol. 13(43), 5754-5759 (2007).
61. American Joint Committee on Cancer. Cancer Staging Manual. Edge SB,Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, NY, USA (2010).
62. de Jong MC, Hong SM, Augustine MM et al. Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch. Surg. 146(6), 697-703 (2011).
63. Deoliveira ML, Schulick RD, Nimura Y et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53(4), 1363-1371 (2011).
64. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch. Surg. 137(6), 675-680; discussion 680 (2002).
65. Melendez J, Ferri E, Zwillman M et al. Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J. Am. Coll. Surg. 192(1), 47-53 (2001). (Pubitemid 32064097)
66. Vauthey JN, Baer HU, Guastella T, Blumgart LH. Comparison of outcome between extended and nonextended liver resections for neoplasms. Surgery 114(5), 968-975 (1993). (Pubitemid 23336115)
67. Tsao JI, Loftus JP, Nagorney DM, Adson MA, Ilstrup DM. Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis. Ann. Surg. 220(2), 199-205 (1994). (Pubitemid 24309419)
68. Makuuchi M, Thai BL, Takayasu K et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107(5), 521-527 (1990). (Pubitemid 20156653)
69. Hemming AW, Reed AI, Howard RJ et al. Preoperative portal vein embolization for extended hepatectomy. Ann. Surg. 237(5), 686-691; discussion 691 (2003).
70. Madoff DC, Hicks ME, Vauthey JN et al. Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics 22(5), 1063-1076 (2002).
71. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br. J. Surg. 88(2), 165-175 (2001). (Pubitemid 32142701)
72. Nagino M, Nimura Y, Kamiya J et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 21(2), 434-439 (1995).
73. Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J. Hepatobiliary. Pancreat. Surg. 7(2), 128-134 (2000).
74. Seyama Y, Kubota K, Sano K et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann. Surg. 238(1), 73-83 (2003). (Pubitemid 38176410)
75. Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J. Clin. Oncol. 15(3), 947-954 (1997). (Pubitemid 27106276)
76. Nimura Y, Kamiya J, Kondo S et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J. Hepatobiliary. Pancreat. Surg. 7(2), 155-162 (2000).
77. Todoroki T, Kawamoto T, Koike N et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br. J. Surg. 87(3), 306-313 (2000). (Pubitemid 30156356)
78. Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann. Surg. Oncol. 13(6), 872-880 (2006). (Pubitemid 43727373)
79. Gerhards MF, van Gulik TM, de Wit LT, Obertop H, Gouma DJ. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma-a single center experience. Surgery 127(4), 395-404 (2000). (Pubitemid 30225991)
80. Jarnagin WR, Bowne W, Klimstra DS et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann. Surg. 241(5), 703-712; discussion 712 (2005).
81. Neuhaus P, Jonas S, Bechstein WO et al. Extended resections for hilar cholangiocarcinoma. Ann. Surg. 230(6), 808-818; discussion 819 (1999).
82. Ito F, Agni R, Rettammel RJ et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann. Surg. 248(2), 273-279 (2008).
83. Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. J. Hepatobiliary. Pancreat. Surg. 7(2), 115-121 (2000).
84. Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann. Surg. 238(1), 84-92 (2003). (Pubitemid 38176411)
85. Kondo S, Hirano S, Ambo Y et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann. Surg. 240(1), 95-101 (2004). (Pubitemid 38808240)
86. Nimura Y, Hayakawa N, Kamiya J, Kondo S, Shionoya S. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J. Surg. 14(4), 535-543; discussion 544 (1990).
87. Cannon RM, Brock G, Buell JF. Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB (Oxford) 14(2), 142-149 (2012).
88. Rea DJ, Munoz-Juarez M, Farnell MB et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch. Surg. 139(5), 514-523; discussion 523 (2004).
89. Gazzaniga GM, Filauro M, Bagarolo C, Mori L. Surgery for hilar cholangiocarcinoma: an Italian experience. J. Hepatobiliary. Pancreat. Surg. 7(2), 122-127 (2000).
90. Kow AW, Wook CD, Song SC et al. Role of caudate lobectomy in type III a and III b hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J. Surg. 36(5), 1112-1121 (2012).
91. Kitagawa Y, Nagino M, Kamiya J et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann. Surg. 233(3), 385-392 (2001). (Pubitemid 32187818)
92. Muñoz L, Roayaie S, Maman D et al. Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J. Hepatobiliary. Pancreat. Surg. 9(2), 237-241 (2002). (Pubitemid 34662322)
93. Hemming AW, Kim RD, Mekeel KL et al. Portal vein resection for hilar cholangiocarcinoma. Am. Surg. 72(7), 599-604; discussion 604 (2006).
94. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann. Surg. 238(5), 720-727 (2003). (Pubitemid 38182264)
95. Nuzzo G, Giuliante F, Ardito F et al.; Italian Chapter of the International Hepato-Pancreato-Biliary Association. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch. Surg. 147(1), 26-34 (2012).
96. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J. Surg. 31(6), 1256-1263 (2007). (Pubitemid 47029903)
97. Park SW, Park YS, Chung JB et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology 51(60), 1612-1618 (2004). (Pubitemid 39389743)
98. Schiffman SC, Reuter NP, Mcmasters KM, Scoggins CR, Martin RC. Overall survival peri-hilar cholangiocarcinoma: R1 resection with curative intent compared to primary endoscopic therapy. J. Surg. Oncol. 105(1), 91-96 (2011).
99. Rao S, Cunningham D, Hawkins RE et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br. J. Cancer 92(9), 1650-1654 (2005). (Pubitemid 40756474)
100. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer 96(6), 896-902 (2007). (Pubitemid 46452283)
101. Valle J, Wasan H, Palmer DH et al.; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273-1281 (2010).
102. Murakami Y, Uemura K, Sudo T et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J. Gastrointest. Surg. 13(8), 1470-1479 (2009).
103. Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a Phase 2 study. Lancet Oncol. 11(12), 1142-1148 (2010).
104. Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a Phase 2 study. Lancet Oncol. 11(1), 48-54 (2010).
105. Bengala C, Bertolini F, Malavasi N et al. Sorafenib in patients with advanced biliary tract carcinoma: a Phase II trial. Br. J. Cancer 102(1), 68-72 (2010).
106. Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am. J. Surg. 159(1), 91-97; discussion 97 (1990).
107. Pitt HA, Nakeeb A, Abrams RA et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann. Surg. 221(6), 788-797; discussion 797 (1995).
108. Zlotecki RA, Jung LA, Vauthey JN, Vogel SB, Mendenhall WM. Carcinoma of the extrahepatic biliary tract: surgery and radiotherapy for curative and palliative intent. Radiat. Oncol. Investig. 6(5), 240-247 (1998).
109. Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg. Today 35(7), 548-552 (2005). (Pubitemid 40854019)
110. Todoroki T, Ohara K, Kawamoto T et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46(3), 581-587 (2000). (Pubitemid 30100635)
111. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur. J. Surg. Oncol. 33(2), 202-207 (2007). (Pubitemid 46336554)
112. Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J. Surg. 27(2), 173-179 (2003). (Pubitemid 36920167)
113. Stein DE, Heron DE, Rosato EL, Anné PR, Topham AK. Positive microscopic margins alter outcome in lymph nodenegative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am. J. Clin. Oncol. 28(1), 21-23 (2005). (Pubitemid 40209319)
114. Ohnishi H, Asada M, Shichijo Y et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology. 42(3), 265-268 (1995).
115. Kuvshinoff BW, Armstrong JG, Fong Y et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br. J. Surg. 82(11), 1522-1525 (1995).
116. Minn AY, Koong AC, Chang DT. Stereotactic body radiation therapy for gastrointestinal malignancies. Front. Radiat. Ther. Oncol. 43, 412-427 (2011).
117. Momm F, Schubert E, Henne K et al. Stereotactic fractionated radiotherapy for Klatskin tumours. Radiother. Oncol. 95(1), 99-102 (2010).
118. Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 39(6), 852-855 (1996). (Pubitemid 27049089)
119. Fingar VH, Wieman TJ. Studies on the mechanism of photodynamic therapy induced tumor destruction. Proc. SPIE 1203, 168-177 (1990).
120. Wong Kee Song LM, Wang KK, Zinsmeister AR. Mono-l-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 82(2), 421-427 (1998). (Pubitemid 28060262)
121. Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surg. Oncol. 16(4), 277-291 (2007). (Pubitemid 350193317)
122. Berr F, Wiedmann M, Tannapfel A et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 31(2), 291-298 (2000). (Pubitemid 30078590)
123. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol. 100(11), 2426-2430 (2005).
124. Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125(5), 1355-1363 (2003). (Pubitemid 37409755)
125. Cheon YK, Lee TY, Lee SM, Yoon JY, Shim CS. Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford). 14(3), 185-193 (2012).
126. Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a Phase II pilot study. Cancer 97(11), 2783-2790 (2003). (Pubitemid 36605146)
127. Petersen BT, Chuttani R, Croffie J et al. Photodynamic therapy for gastrointestinal disease. Gastrointest. Endosc. 63(7), 927-932 (2006). (Pubitemid 43776149)
128. Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J. Am. Coll. Surg. 187(4), 358-364 (1998). (Pubitemid 28467610)
129. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69(8), 1633-1637 (2000).
130. Shimoda M, Farmer DG, Colquhoun SD et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 7(12), 1023-1033 (2001). (Pubitemid 34023989)
131. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl. Int. 23(7), 692-697 (2010).
132. Murad SD, Ray Kim W, Therneau T et al. Predictors of pre-transplant dropout and post-transplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology doi:10.1002/hep.25629 (2012) (Epub ahead of print).
133. Hong JC, Jones CM, Duffy JP et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch. Surg. 146(6), 683-689 (2011).
134. Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242(3), 451-458; discussion 458 (2005).
135. Patel T. Cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(1), 33-42 (2006). (Pubitemid 43102075)